In this Life Sciences – In Focus conversation with Dr. Simran Padam, Executive Director, Medical Affairs at Worldwide Clinical Trials, we discuss a physician’s perspective on some of the most complex questions facing clinical development today. With nearly two decades of experience across oncology, clinical research, and drug development, Dr. Padam explores what happens when carefully designed protocols meet the realities of individual patients, why the medical monitor’s role extends far beyond safety review, and what the next generation of precision medicine and cell and gene therapies could mean for cancer drug development.
From Treating One Patient to Impacting Thousands
Like many physicians, Dr. Padam initially envisioned a traditional medical career: rotations, board exams, residency, and clinical practice. But while working with patients, she began asking an important question: What happens when standard-of-care treatment options run out? Encouraged by mentors to explore clinical research, she discovered another side of medicine, one concerned not only with treating the patient in front of you, but with developing therapies that could ultimately affect hundreds or thousands of patients.
That potential for impact proved compelling, particularly in oncology, where scientific advances can move rapidly from the laboratory into clinical trials and eventually transform patient care. After almost two decades in the field, that sense of discovery remains. As Dr. Padam explains, even a single patient can reveal something about a clinical trial that researchers never anticipated.
When the Protocol Meets the Patient
One of the most important lessons Dr. Padam has learned is that a clinical trial protocol, however carefully constructed, cannot answer every situation. Protocols establish essential structure. They define eligibility criteria, dose modifications, laboratory thresholds, and other parameters required to conduct research consistently. But real patients rarely fit perfectly within those definitions.
This becomes especially apparent in oncology. A patient with advanced cancer may have undergone several previous therapies, have multiple comorbidities, and be taking numerous concomitant medications. If that patient suddenly develops elevated liver enzymes, for example, determining the cause is rarely straightforward. Is the investigational therapy responsible? Is the cancer progressing? Could another medication be contributing? The protocol provides the framework, but answering those questions requires medical judgment and an understanding of the patient’s complete clinical story. Dr. Padam also highlights another important principle: behind every table, laboratory trend, adverse event, and data listing is a patient. Understanding that human story is essential to interpreting the data correctly.
How the Medical Monitor Role Is Evolving
Medical monitors are often perceived primarily as physicians who review safety information, answer eligibility questions, and become involved when serious adverse events occur.
Patient safety remains fundamental, but Dr. Padam argues that the modern medical monitor occupies a much broader and increasingly strategic position.
“We’re at the core or the center of a clinical trial,” she explains.
Medical monitors sit at the intersection of the patient, investigator, site, protocol, and emerging clinical data. That perspective lets them identify patterns that may not be visible elsewhere. One eligibility question from a site may simply require an answer. But when several sites repeatedly ask essentially the same question, it may indicate something bigger: unclear protocol language, overly restrictive eligibility criteria, or insufficient site training. At that point, medical monitoring becomes more than responding to individual cases. It becomes a way to identify and help resolve study-level problems.
The same applies to enrollment challenges. If recruitment is slow, adding more sites may appear to be the obvious solution. But the underlying problem could instead be an eligibility criterion causing screen failures, an overly burdensome study design, or sites not seeing the appropriate patient population.
Effective medical monitors therefore need to move between two perspectives: the individual patient and the overall clinical development program.
Why Clinical Judgment Matters in Early-Phase Oncology
This combination of protocol structure and clinical judgment becomes particularly important in Phase I and first-in-human oncology studies. Patients entering these studies are often heavily pretreated and may already have compromised bone marrow reserve or borderline liver or kidney function. Once an investigational therapy is introduced, interpreting subsequent adverse events and laboratory abnormalities can become complex.
Dr. Padam uses elevated liver enzymes as an example. Investigators may need to consider extensive liver metastases, disease progression, concomitant medication, baseline abnormalities, and the investigational treatment itself before determining the likely cause. She also cautions against viewing the dose-limiting toxicity (DLT) period as the only clinically significant window. Adverse events occurring after that period may still be treatment-related and provide important information for understanding a therapy’s safety and determining dose-escalation decisions. The challenge is to continually ask whether an event represents an individual patient issue or whether it could signal a broader study-level concern.
Good Science Alone Does Not Guarantee a Successful Trial
A scientifically promising therapy is only the starting point. For that science to have a fair chance of succeeding, the clinical trial must also be designed and executed effectively. Dr. Padam points to several factors that can undermine otherwise strong science: a poorly designed protocol, an unreliable biomarker assay, inconsistent adverse-event assessment between sites, delays in medical decision-making, and ineffective communication across teams.
Something as seemingly straightforward as a delayed response to an eligibility question can have consequences for enrollment, timelines, patient safety, and site confidence. Communication is therefore not simply an operational convenience. Clinical development brings together investigators, sponsors, safety teams, vendors, and numerous other stakeholders. Their ability to collaborate effectively can directly influence whether a trial succeeds.
Precision Medicine Is Changing Cancer Drug Development
Looking ahead, Dr. Padam sees cancer treatment continuing its shift away from defining disease primarily by where a cancer originates and toward understanding the specific biology of each patient’s cancer. Two people may both have lung cancer, for example, while having cancers that differ substantially at the molecular level, and therefore require very different treatments.
This evolution will place even greater emphasis on precise biomarkers, blood-based approaches to monitoring tumors, improved diagnostics, and a deeper understanding of the mechanisms that make cancers resistant to treatment. At the same time, targeted therapies, antibody-based treatments, radiopharmaceutical approaches, and cell and gene therapies are reshaping early development.
As treatments become increasingly precise, however, finding eligible patients can become more difficult. Biomarker testing, site selection, and enrollment planning therefore need to be considered early, ideally before the first patient enters the study.
Cell and Gene Therapies Require a Different Development Mindset
Cell and gene therapies create another fascinating challenge. These treatments can involve unique risks, complicated manufacturing requirements, and long-term safety considerations. And as they move beyond oncology into areas such as autoimmune and other chronic diseases, the assumptions used to assess benefit and risk may also need to change. A patient with advanced cancer and few remaining treatment options may be prepared to accept substantial treatment risks. The calculation can look very different for a younger patient living with a chronic autoimmune disease who may otherwise expect to live for many years.
For that reason, Dr. Padam argues that the industry cannot simply take the existing oncology model for cell and gene therapy and transfer it unchanged into other therapeutic areas. Scientific innovation is accelerating rapidly. The challenge now is ensuring that clinical development systems and operational teams can keep pace. “It’s not only about creating smarter treatments,” Dr. Padam says, “but it’s also about building smarter systems to develop and deliver these treatments.”
Clinical Research Is Still Medicine – Practiced Differently
Dr. Padam closes the conversation with an important message for physicians considering a move from clinical practice into industry. Making that transition can sometimes feel like “leaving medicine.” She sees it differently. Instead of making decisions for one patient at a time, physicians working in clinical research can contribute to decisions that may eventually affect thousands of patients.
That transition requires learning how clinical trials, regulation, safety, protocols, and drug development work. It also requires something that came up repeatedly throughout the conversation: collaboration.
Clinical development is fundamentally a team effort. For physicians interested in exploring this path, Dr. Padam recommends talking to people already working in the industry, seeking mentorship early, and building connections.
Her career and perspective offer a compelling reminder that behind every protocol, endpoint, adverse event, and dataset is a patient, and that advancing medicine requires both scientific rigor and the clinical judgment to understand what the data is really telling us.
About Life Sciences – In Focus
Life Sciences – In Focus Podcast by Visatatec, a fascinating conversation with global life sciences experts. The show has multiple hosts and topics. Follow Life Sciences – In Focus on Spotify for all the latest episodes, or subscribe to the show on YouTube and Apple podcasts. Life Sciences – In Focus is available on many other podcast platforms. To learn more about the podcast, please visit www.vistatec.com/life-sciences-division
About Vistatec
We have been helping some of the world’s most iconic brands to optimize their global commercial potential since 1997. Vistatec is one of the world’s leading global content solutions providers. HQ in Dublin, Ireland, with offices in Mountain View, California, USA. To learn more about Vistatec, please visit https://www.vistatec.com